- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hypertrophic cardiomyopathy
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 761KB)
Mavacamten – July 2023
Mavacamten: Capsule 2.5 mg, Capsule 5 mg, Capsule 10 mg, Capsule 15 mg; Camzyos®
Last updated
27 October 2023